07:00 , Jun 17, 2013 |  BioCentury  |  Finance

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical but...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Gene Techno Science completes IPO

Gene Techno Science Co. Ltd. (Tokyo:4584), Sapporo, Japan   Business: Cancer, Autoimmune, Musculoskeletal   Date completed: 11/30/12   Type: IPO   Raised: ¥696 million ($8.4 million)   Shares: 580,000   Price: ¥1,200   Shares after offering: 2 million   Underwriters: Nomura; Mizuho; Ichiyoshi;...
07:00 , Jul 9, 2007 |  BC Week In Review  |  Company News

Gene Techno Science, Kaken deal

Gene Techno granted Kaken an exclusive, worldwide license to develop, manufacture and market antibodies that target integrin alpha(9). The companies will collaborate on preclinical R&D of the antibodies to treat autoimmune and bone diseases....